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ABSTRACT 
Community acquired pneumonia (CAP) is the most commonly occurring infectious 
disease that requires hospital admission. CAP affects mainly, the youngest, the oldest, 
the poorest and the sickest. Annual incidence is 5-12 per 1000 adults. Between 20% 
and 40% of patients with CAP need in-hospital treatment. Mortality is below 1% 
among those who are treated in the community, however in-hospital mortality can be as 
high as 50% in patients who are critically ill due to CAP. In Europe the annual costs 
from pneumonia is estimated to be more than €10 billion. Streptococcus pneumonia is 
the main aetiology of CAP, as well as it carries the highest fatality rate. In the pre-
antibiotic era the observed death toll from bacteraemic pneumococcal pneumonia could 
reach, and even exceed, 80%. Today, with access to effective antibiotics the observed 
fatality rate from bacteraemic pneumococcal pneumonia usually varies between 5% 
and 25%. 
 
In paper 1, 460 patients were included, from five centres in five countries, in a 
prospective multicentre study. All patients had pneumococcal bacteraemic disease and 
12% of the patients died during period of hospitalisation. Independent prognostic 
factors of death present on admission were age >65 years, chronic pulmonary disease, 
nursing home residency, high Acute Physiologic and Chronic Health Evaluation 
(APACHE II) score, and >2 lung lobes affected.  Need for mechanical ventilation after 
admission was also an independent prognostic risk factor for death.  
 
In paper 2, 340 patients with pneumonia, included in paper 1, were analysed. Aim of 
the study was to examine if the combination of β-lactam and macrolide antibiotics 
could reduce the case fatality rate (CFR) in patients with bacteraemic pneumococcal 
pneumonia. Despite use of univariate, as well as multivariate analysis, we were unable 
to find any reduction in fatality rate among patients, with bacteraemic pneumococcal 
CAP, who received antibiotic combination therapy. 
 
Paper 3 included 375 patients who all suffered from bacteraemic pneumococcal 
pneumonia and were enrolled during two periods of time, 1993-1995 and 1999-2000. 
Patients enrolled during the first time period were identical with the Swedish patients 
who took part in the studies described in paper 1 and 2. In paper 4, 1172 patients were 
included from one hospital during 16 months. All patients in paper 4 had pneumonia of 
different microbial aetiology. In both papers the proposed, and modified new scoring 
system, DS CRB-65, proved to be significantly more accurate, than CRB-65, to predict 
30-day mortality in patients with bacteraemic pneumococcal CAP, as well as in patients 
with CAP of different microbial aetiology. 
 
Keywords: β-lactam, macrolide, pneumonia, prognosis, scoring system, Streptococcus 
pneumoniae,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Men of good fortune 
 
Often cause empires to fall 
 
While men of poor beginnings 
 
 Often can´t do anything at all 
Lou Reed 
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1 INTRODUCTION 
1.1 HISTORY 
Man has known pneumonia for thousands of years and it is believed that Hippocrates 
(400 B.C.) has described pneumonia and its treatment (1). Hepatisation of lung tissue is 
described in an ancient Egyptian mummy (1). In 1819, and 1820 Laennec made the 
first “modern” characterisation of the disease, depicted the physical signs and 
pathologic changes of pneumonia, and was able to distinguish between “pneumonia” 
and “pleurisy” (1). Most of the main bacterial causes of pneumonia were defined by the 
late 1930s (1). Streptococcus pneumoniae, that was first isolated in 1881, by Pasteur (2, 
3) and Sternberg (4, 5) was then, and is still today, the leading microbiological cause of 
pneumonia, found to account for two thirds of all 7000 cases with an established 
aetiology in a meta-analysis of 122 reports between the years 1966 and 1995 (6). In the 
pre-antibiotic era approximately 700 cases of pneumonia occurred in 100 000 young 
adults each year (1), and due to the seriousness of the disease with an observed case 
fatality rate CFR of more than 80% in patients with bacteraemic pneumococcal lobar 
pneumonia (1), many different remedies were tried such as alcohol, caffeine, 
strychnine, epinephrine, quinine, hydrotherapy, flaxseed poultice, serum therapy. Of 
these different therapies, treatment with specific antiserum in patients with serious 
pneumococcal pneumonia, was probably the most beneficial therapy, and could in 
some series of patients half the CFR (1). With optochin, a quinine derivative, the first 
attempt to treat pneumococcal infections with an antimicrobial chemotherapeutic agent 
was made. Morganroth and Levy showed that optochin inhibited growth of 
pneumococci in vitro (7). Unfortunately pneumococci rapidly became resistant (8). In 
addition optochin demonstrated optic toxicity (9) and was therefore abandoned from 
clinical use (10). 
The second antimicrobial chemotherapeutic drug to be used in the treatment of patients 
who suffered from pneumococcal disease was sulphanilamide. As the pneumococcus 
was not as highly susceptible to sulphanilamide as Streptococcus pyogenes, search for a 
chemical compound related to sulphanilamide, however less toxic and more efficient 
began. Whitby (11) found in 1938, after undertaking systemic research the chemical 
compound pyridine or sulphapyridine. Only five weeks after Whithby´s work Evans 
and Gaisford (12) reported in The Lancet that treatment with sulphapyridine reduced 
the CFR among patients with lobar pneumococcal pneumonia from 27% to 8%. 
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Pyridine seemed to be the drug of choice for patients with pneumococcal infections; 
however, in 1943 sulphonamide-resistant strains were reported (13). 
Though penicillin, when compared with sulphanilamid, possessed greater potency per 
unit, lack of interference by breakdown products, minimal interference of inoculum 
size on effectiveness, and no resistant pneumococcal strains, it took several years after 
the discovery of penicillin before it could replace the sulphonamide antibiotics. In the 
early 1940s it became possible to synthesise larger quantities of penicillin for the 
treatment of pneumococcal infections (14). 
 
1.2 EPIDEMIOLOGY  
Pneumonia is a very common clinical disorder. Community acquired pneumonia (CAP) 
in Western countries has an estimated annual incidence between 5 and 12 cases per 
1000 persons (15-18). In the United States of America (USA) it is the second most 
common cause of hospitalisation after hospital admission due to childbirth (19), the 
sixth leading cause of death in those 65 years or older, and the most common cause of 
infection related mortality (20). The annual financial burden of pneumonia in Europe 
was in 2003, as estimated by the European Respiratory Society, €10.1 billion, including 
costs for hospitalisation accounting for €5.7 billion (21). In a study by Welte and 
colleagues (22), this year, the costs for absences from work in Europe, due to CAP, was 
estimated to be €3.6 billion. 
Age is a factor that has great impact on annual incidence of CAP. This was well 
demonstrated in the study by Jokinen et al. (16) where the annual incidence in age 
group 16-59 was 6/1000 persons, for those aged 60 and over, it was 20/1000 persons 
and for age 75 years and over, it was 34/1000. The proportion of adults with CAP who 
required in-hospital treatment in the Finnish prospective longitudinal population study 
was 42% (16). In two British studies it was reported that between 22% and 42% of 
patients with CAP needed hospital care (15, 23). Patients with CAP who required 
intensive care unit (ICU)-management was 5% in a multicentre study by the British 
Thoracic Society (BTS) (24), and 10% in a Spanish study (25). 
Mortality in patients treated for CAP is low among non-hospitalised patients in the 
community and the CFR is usually below 1% (26-28). Among patients admitted for 
hospital treatment in Europe the CFR has been observed to vary between 2.6% (29) and 
14% (30). In an international cohort study that included more than 13 000 patients, 
published in May this year (31), mortality at 30 days was 8%. The 30-day mortality 
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among Swedish CAP-patients admitted to hospital, and treated in infectious diseases 
departments, was 2.6% in a study by Strålin et al. (29). In another Swedish study 
Johansson et al. (32) reported a CFR during hospitalisation of 3.8%. Many factors have 
been proposed, as well as discussed, that increase the risk of developing or dying from 
CAP. In the prognostic scoring systems, used for initial assessment of CAP, included 
and discussed in this thesis, risk factors associated with mortality in pneumonia are 
listed. However, in western countries old age is a most important (perhaps the most 
important) risk factor for both developing and dying of CAP (33). Many underlying, or 
concomitant diseases, prognostically unfavourable for patients with CAP, are age 
dependant and infrequently observed in the young and middle aged. 
Today, as in the pre-antibiotic era, the leading bacterial cause of pneumonia, 
meningitis, and acute otitis media is the ubiquitous Gram-positive diplococcus, 
Streptococcus pneumoniae. Though pneumococcal disease affects people of all ages, it 
is the youngest and the oldest who are most often affected by pneumococcal infections. 
Pastor et al. (34) reported in a study from the USA an annual incidence of invasive 
pneumococcal disease of 136/100 000 persons under two years of age, as well as 
80/100 000 persons over 65 years of age (overall annual incidence was 22/100 000 
persons). In the same study Pastor additionally reported an increased incidence of 
invasive pneumococcal disease among low-income groups, as well as in the black 
community. As penicillin, and other antibiotic compounds, became accessible to 
patients with infectious diseases after the Second World War it was believed that 
pneumococcal disease was no longer a major problem among the infectious diseases. 
However, Austrian and Gold (35) revealed in 1964 that bacteraemic pneumococcal 
disease was still to fear. In their study they reported that the CFR of all patients with 
bacteraemic pneumococcal pneumonia was almost 20%, CFR in patients with 
pneumococcal meningitis was above 60%, and the CFR nearly reached 30% among 
patients with bacteraemic pneumococcal pneumonia who were 50 years of age or older. 
In the USA invasive pneumococcal disease still is a major infectious disease issue and a 
CFR exceeding 35% has been noted (36-41). The CFR among patients with 
bacteraemic pneumococcal pneumonia has in Sweden during the last three decades 
been observed to range between 5% and 11.5% (37-40). 
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1.3 ANTIBIOTIC COMBINATION THERAPY OF BACTERAEMIC 
PNEUMOCOCCAL PNEUMONIA 
In many guidelines for the management of patients with severe CAP, therapy with a β-
lactam antibiotic combined with a macrolide, or a “respiratory tract quinolone” 
(levofloxacin, moxifloxacin), has been recommended to cover atypical pathogens as 
Legionella species, as well as Mycoplasma pneumoniae (42, 43). Some studies, most of 
them retrospective, have shown that combination therapy also has a beneficial effect on 
CFR in patient with bacteraemic pneumococcal pneumonia, and this issue has become 
a matter of debate among medical researchers (44-46). The mechanism, or 
mechanisms, that mediate the alleged favourable effects in patients with bacteraemic 
pneumococcal pneumonia have not yet been found or explained. However, many 
explanations have been proposed for this effect such as concomitant infection with an 
atypical bacterial pathogen, particularly Legionella species (47, 48), pulmonary anti-
inflammatory and immunomodulatory effects (49, 50), as well as effects regarding 
difference in killing rates among antimicrobial drugs, antibiotic synergism, antibiotic 
tolerant pneumococci, or pneumococci adherent to respiratory epithelial cells (51, 52). 
However, none of these proposed explanations have yet proved to be clinically 
important, and a mouse peritonitis model has demonstrated antagonism between 
penicillin and erythromycin (53, 54). Excessive use of antibiotics always increases the 
risk of resistance developing in microorganisms, as well as other adverse effects. The 
macrolide antibiotics are known for their cardiotoxic, pro-arrhythmic, effects that in 
some patients have led to sudden death (55-59). 
 
1.4 PROGNOSTIC SCORING SYSTEMS FOR THE ASSESSMENT OF 
PATIENTS WITH PNEUMONIA 
Community acquired lower respiratory tract infections are common, observed and 
handled at all levels of the health care system. Patients with CAP can be managed in 
many different ways due to the seriousness of the disease: as outpatients, sometimes 
provided with ambulatory care, in the hospital after admission, or on the ICU in severe 
cases. Due to the frequency and complexity of CAP many prognostic scoring systems 
for the initial assessment of CAP-patients have been created and tested. 
A multicentre prospective survey of aetiology, mortality, prognostic factors, and 
outcome including 453 patients with CAP from 25 British hospitals was performed by 
the BTS and the Public Health Laboratory during the years 1982-1983 (60). The study 
was published in 1987. One of the main result of this study (the BTS rule) was that 
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included study patients had a 21-fold increased risk of death if 2 of the 3 following 
signs were observed on hospital admission: respiratory rate >30/minute, diastolic blood 
pressure (BP) <60 millimetres of mercury (mmHg), serum urea >7 millimoles per litre 
(mmol/l). Nine years after the BTS rule was published Neill, and colleagues, in New 
Zeeland, published their study of 255 prospectively collected patients with CAP (61). 
Neill et al. modified the BTS rule (mBTS) by adding the sign confusion present on 
hospital admission. If two, or more signs (tachypnea, low diastolic BP, elevated urea, 
confusion) were present on hospital admission patients had a 36-fold risk of death. The 
BTS and mBTS rules lay the ground for CURB-65, as well as the CRB-65 (62), as 
more than 1000 patients with CAP from the United Kingdom (UK), the Netherlands, 
and New Zeeland were prospectively studied. The two latter scoring systems proposed 
by the BTS (63) to be used for initial assessment of patients with CAP. The CURB-65 
score contains 5 parameters, giving a 6-point score: Confusion, Urea >7 mmol/l, 
Respiratory rate >30/minute, Blood pressure <90 mmHg systolic, or <60 mmHg 
diastolic, age >65 years. The CRB-65, studied in over 6000 patients (63), and originally 
intended to be used in the outpatient setting, does not require any laboratory 
measurements, and is therefore simple to use as a bedside tool when assessing the 
CAP-patient. Though, the CRB-65 contains only clinical parameters, the CURB-65, 
and the CRB-65 have performed equally well at discriminating patients into mortality 
risk groups (63). The Swedish Society of Infectious Diseases (Svenska 
Infektionsläkarföreningen) recommends the use of CRB-65 for initial assessment of 
patients with CAP, as the scoring system is well studied and easy to use (42). 
Developed in the USA, by Fine and colleagues, the Pneumonia Severity Index (PSI) 
(also called PORT score, as well as Fine score) (64), is the most widely studied 
predictive model in the management of CAP. The PSI is based on 20 variables, with 
different weight, that are used to derive a score. Based on 30-day mortality the score 
enables patient to be stratified into five risk classes, or categories. The PSI was 
developed to identify patients who were at low risk of death and who could be safely 
managed outside the hospital, and it is in the outpatient setting where the PSI has best 
been evaluated. The PSI has been studied worldwide in over 50 000 patients, and it is 
probably the best validated scoring system for identifying patients at low risk of death 
from CAP (64, 65).  
As life expectancy is rising, the western worlds population is aging, and as people 
become older the number of persons who are medically compromised will increase, 
many of whom will require treatment for CAP (66). The PSI emphasis on age and 
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underlying medical conditions, two parameters that in the future probably will become 
of even greater importance than today when deciding sites of care in patients with CAP. 
Hypoxaemia is, as well one of the parameters included in the PSI. Several studies have 
found that low oxygenation on admission is an unfavourable prognostic factor in CAP 
(64, 67, 68). Sanz et al. (69) revealed that in patients with a low CURB-65 score (0-1), 
decreased oxygenation on admission was independently associated with adverse 
outcome. However, the PSI is cumbersome and time consuming to use with its 20 
parameters, even when web based calculators are used for computation of the score. A 
scoring system for initial assessment of patients with CAP that include comorbidity, as 
well as oxygenation, both parameters included in the PSI, may have potential to help 
physicians and health care personnel who need to assess patients with CAP.  
The PSI, CURB-65, and CRB-65 are still the most thoroughly evaluated scoring 
systems for initial prognostic assessment of patient with CAP in regard to 30-day 
mortality (63). Other prognostic scoring systems as A-DROP (70), SMART-COP (71), 
and SCAP (72) have been tested and evaluated in patients with pneumonia. These three 
scoring systems require at least one laboratory analysis, radiography, or some other 
nonclinical parameter to be measured before the scores can be calculated, and 
employed. The Acute Physiologic and Chronic Health Evaluation (APACHE II) (73) 
scoring system, common in the ICU-setting has, as well been used to measure severity 
of illness in patients with CAP (74-76) and in patients with bacteraemic pneumococcal 
disease (37). However, the APACHE II scoring system includes several laboratory 
parameters that require chemical analysis before the total score can be calculated. 
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2 AIMS 
2.1 GENERAL AIMS 
To investigate underlying prognostic factors impact on CFR in community acquired 
Streptococcus pneumoniae bacteraemia with especial emphasis on pneumonia. Analyse 
if a β-lactam-macrolide combination reduces CFR in patients with bacteraemic 
pneumococcal pneumonia. To evaluate and improve prognostic scoring systems that 
are easy to apply for initial assessment in patients with CAP. 
 
2.2 SPECIFIC AIMS 
PAPER 1 
To identify and define the influence of risk factors in patients >18 years old with 
community acquired pneumococcal bacteraemia. 
PAPER 2 
To analyse if the addition of a macrolide to a β-lactam reduces mortality in patients 
with bacteraemic pneumococcal CAP. 
PAPER 3 
In adult patients with bacteraemic pneumococcal CAP compare the accuracy of three 
well established scoring systems (PSI, CURB-65, CRB-65) used for the initial 
assessment of patients with CAP, and to investigate the potential to improve CRB-65, 
while retaining its simplicity. 
PAPER 4 
To test and to further improve a modified CRB-65, as a prognostic scoring system in 
adult patients with CAP of different microbial aetiology, as well as to specify a scoring 
point level to facilitate the decision which patients, with CAP, that might safely be 
treated as outpatients, or may benefit from inpatient care. 
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3 MATERIALS AND METHODS 
3.1 PATIENTS AND MATERIALS 
 
3.1.1 Paper 1 
From five cites in five countries (Sweden, Spain, Canada, England, and the USA) a 
total of 460 patients were prospectively included in the study during two years, from 
September 1993, through August 1995. All patients were admitted to hospital, had not 
been hospitalised during the preceding 30 days before admission, had pneumococcal 
bacteraemia, and were aged 18 years and above. An identical case report form was used 
for all patients in the study.  
 
3.1.2 Paper 2 
Of the 370 patients who participated in the first study (paper 1), and suffered from 
bacteraemic pneumococcal pneumonia, 340 patients who were treated with a ß-lactam 
antibiotic, with or without the addition of a macrolide, were studied. All patients had a 
new radiographic shadowing on chest x-ray, consistent with pneumonia. Antibiotics 
received by the patients during the two first days in hospital were defined as initial 
antibiotic therapy. The study was observational. 
 
3.1.3 Paper 3 
All 233 patients who were enrolled at the Swedish study centre, in paper 1, and 
suffered from bacteraemic pneumococcal pneumonia were included in paper 3. In order 
to increase the number of participants in the study another 142 patients with community 
acquired bacteraemic pneumococcal pneumonia were retrospectively recruited from 
Karolinska University Hospital and Södersjukhuset, from January 1999 through 
December 2000, by use of the same case report form (CRF) and inclusion criteria, as 
the patients enrolled in paper 1 and 2. 
 
3.1.4 Paper 4 
From Södersjukhuset, an inner city teaching hospital, patients were retrospectively 
enrolled during a 16-month period, from December 2008 through March 2010. A total 
of 1172 patients were recruited, of which 830 patients were admitted for inpatient 
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treatment, and 342 patients were assigned to ambulatory treatment after their visit at the 
emergency department (ED). Patients had not been hospitalised during the preceding 
two weeks before enrolment, and all patients, except 144 outpatients, had a new 
radiographic finding on chest x-ray, or chest computed tomography (CT), consistent 
with pneumonia. All admitted patients had a principal diagnosis of pneumonia, or a 
principal diagnosis of sepsis due to Streptococcus pneumonia, Haemophilus influenzae, 
or Klebsiella pneumoniae plus a secondary diagnosis of pneumonia according to the 
International Classification of Diseases 10th revision (ICD-10) codes. The patients who 
received ambulatory treatment all had a first-listed diagnosis of pneumonia based on 
ICD-10 codes. Clinical charts as well as laboratory parameters were recorded and 
analysed in order to calculate the different scoring systems used for initial assessment 
of patient with community acquired pneumonia. 
 
3.1.5 SUMMARY 
Patients in paper 1-3 all had growth of Streptococcus pneumoniae in blood cultures, 
and were prospectively recruited between September 1993 and August 1995. However, 
in paper 3 were as well 142 patients retrospectively included between January 1999 and 
December 2000. Patients in paper 4 suffered from community acquired pneumonia of 
different aetiology and were enrolled between December 2008 and March 2010, from 
one hospital. Studies 2-4 were observational, and antibiotic treatment received by each 
patient was at the discretion of the responsible physician. 
 
3.2 METHODS 
3.2.1 Prognostic factors 
In all patients the following were to be recorded on admission – age, sex, nursing home 
living, smoking, alcohol, as well as intravenous (IV) narcotic abuse known by medical 
care, chronic disease (cardiac disease – hypertensive and/or arteriosclerotic with or 
without heart failure, pulmonary disease, liver disease, renal disease, diabetes mellitus, 
cancer, autoimmune disease, steroid treatment, human immunodeficiency virus (HIV)-
infection, “other chronic diseases”) date of onset of symptoms, APACHE II score at 
admission (paper 1 and 2), weight and height, serum levels of albumin and C-reactive 
protein, peripheral oxygen saturation measured by pulse oximetry (SpO2). In paper 1 
clinical presentation was recorded as pneumonia, meningitis, endocarditis, arthritis or 
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osteomyelitis, peritonitis, “no focal infection”, as well as combinations of these clinical 
manifestations of bacteraemic pneumococcal disease.  
In all patients need for intensive care unit treatment, and mechanical ventilation were 
recorded, and in paper 1, as well as in paper 2, antibiotic treatment, including treatment 
time and doses, were also recorded. Occurrences, as well as, type of nosocomial 
infections, were recorded in paper 1. In paper 2, in-hospital mortality was compared 
between the study group of patients who received a β-lactam alone, or in combination 
with a macrolide antibiotic, for initial antibiotic therapy. Initial antibiotic therapy was 
defined as the antibiotic therapy received by the patient during the two first days in 
hospital after admission. 
In paper 1, and in paper 2, mortality during hospital stay served as endpoint, while in 
paper 3 and 4 mortality within 30 days of admission was set as endpoint. 
 
3.2.2 Microbiology 
Patients admitted for hospital treatment with suspected bacteraemia or sepsis had blood 
cultures taken. If growth of Streptococcus pneumonia was detected, the study person at 
the site was immediately informed about the finding, and the patient was enrolled in the 
study if inclusion criteria were fulfilled (paper 1). 
 
3.2.3 Severity scores 
In paper 1, and in paper 2, the APACHE II score was used for assessment of disease 
severity. The APACHE II score provides a general measure of severity of disease and it 
is widely used in ICUs. In paper 3 and 4 three well established scoring systems for the 
initial assessment of patients with CAP, the PSI, CURB-65, and CRB-65 were used. 
Severity scores often serve as tools to the clinician to determine the individual patients 
risk of dying and level of care needed. The scoring systems are also often used in 
medical research (studies) involving patients with pneumonia. Clinical findings and 
laboratory results used for the computation of the different scoring systems were, with 
only few reservations, the results found during first contact at the ED. 
The four severity scores were, with few exceptions, calculated in accordance with the 
original publications. When calculating the APACHE II, and the PSI scores, the 
corresponding level of haemoglobin replaced haematocrit. As serum creatinine, instead 
of serum urea, is used in the hospitals were patients were enrolled, cut off values for 
serum urea when PSI was calculated (>11 mmol/l), as well as CURB-65 (>7 mmol/l) 
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were replaced by serum creatinine >130 micromoles per litre (µmol/l) corresponding to 
the higher serum urea level in accordance with a study by Spindler et al. (38). 
Coexisting conditions (see below), and a low oxygen blood level were of independent 
importance for predicting the case fatality rate (CFR) in the study by Fine et al. (64).  
Therefore in paper 3, and in paper 4, we analysed if adding information concerning 
coexisting conditions, as well as peripheral oxygen saturation <90% measured by a 
pulse oximeter (abbreviated as SaO2 in paper 3 and SpO2 in paper 4), or partial pressure 
of oxygen (PaO2) <8 kilopascal (kPa) (paper 3), to CRB-65, could easily improve its 
accuracy of predicting the CFR, without adding any laboratory measures. We let the 
existence of >1 coexisting medical condition increase the scores with 1 point, as well as 
letting the finding of SaO2 <90%, or PaO2 <8 kPa in paper 3 and SpO2 <90% in paper 4 
increase the scores with further 1 point. 
 
3.2.4 Statistics 
Computer software used for statistical analysis were SAS JMP 5.0.1, and SAS 9.0 
(SAS Institute, Cary, NC, USA), SPSS 16.0 (IBM SPSS, Chicago, IL, USA). For the 
construction of receiver operating characteristic (ROC) curves, as well as for the 
comparison of the different ROC-curves, area under the curves (AUCs), the software 
NCSS 07.1.1 was used. 
For estimation of individual factors prognostic importance in paper 1 the Cochran-
Mantel Haenszel method was used to neutralise imbalance between centres. In paper 1-
4 for comparisons of binary type the chi-square, t-test, or Fisher´s exact test were used. 
The Wilcoxon/Kruskal-Wallis rank sum test was used for continuous variables. For the 
estimation of independent risk factors found in univariate analysis to have significant, 
or near significant statistical impact on risk of death, multivariate regression models 
were used. In paper 3 and 4 the AUCs of the ROC-curves were measured for the 
comparison of the different scoring systems accuracy to predict 30-day mortality. To 
find an appropriate cut off value for DS CRB-65 in paper 4 the Youden Index was 
applied. For all analyses a two-sided p-value of less than 0.05 was considered to 
indicate statistical significance. 
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3.2.5 Ethics committee approval 
The studies included in this thesis were approved by the local ethics committee at 
Karolinska Institutet, Karolinska University Hospital. Registration Number:   93:187, 
328:02, 2011/1:3. 
 
 
 
 
 
 
 
The CURB-65 score adapted from the original publication by Lim et al. (62) 
One point for each element that is present, maximum score is 5 (0-5) 
Confusion - new disorientation in person, time or place 
Urea - blood urea nitrogen (BUN) level >7 mmol/l 
Respiratory rate >30/minute 
Blood pressure <90 mm Hg systolic and/or <60 mm Hg diastolic 
Age >65 years 
 
 
 30-day estimated mortality data by risk class 
Risk class Treatment Risk mortality Mortality % 
0 Outpatient Low 0.7 
1 Outpatient Low 2.1 
2 In- or outpatient Intermediate 9.2 
3 Inpatient High 14.5 
4 Inpatient High 40 
5 Inpatient High 14 (1/7 patients) 
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The Acute Physiologic and Chronic Health Evaluation (APACHE II) score 
adapted from the original publication by Knaus et al.(73) 
Physiologic variable +4 +3 +2 +1 0 +1 +2 +3 +4 
Temperature, rectal (0C) >41 39-40.9  38.5-
38.9 
36-38.4 34-35.9 32-33.9 30-31.9 <29.9
Mean arterial pressure, 
(mmHg) 
>160 130-
159 
110-
129 
 70-109  50-69  <49
Heart rate >180 140-
179 
110-
139 
 70-109  55-69 40-54 <39
Respiratory rate >50 35-49  25-34 12-24 10-11 6-9  <5
If FIO2 >0.5 O2 (kPa) >67 47-66 27-46  <27     
If FIO2 <0.5 PaO2 (kPa)     >9.3 8.1-
9.3 
 7.3-
8.0 
<7.3
Arterial pH >7.7 7.6-
7.69 
 7.5-
7.59 
7.33-
7.49 
 7.25-
7.32 
7.15-
7.24 
<7.15
S-Sodium (mmol/l) >180 160-
179 
155-
159 
150-
154 
130-
149 
 120-
129 
111-
119 
<110
S-Potassium (mmol/l) >7 6-6.9  5-5.9 3.5-5.4 3-3.4 2.5-2.9  <2.5
S-Creatinine (µmol/l) 
Double points if acute renal 
failure 
>600 300-
599 
180-
299 
130-
179 
50-129  <49   
Haematocrit (%) >60  50-59.9 46-49.9 30-45.9  20-29.9  <20
White blood count (109/l) >40  20-39.9 15-19.9 3-14.9  1-2.9  <1
Glasgow Coma Score (GCS) See specified below      
Chronic Health Evaluation See specified below      
Age See specified below      
 
Glasgow Coma Scale (GCS): 
GCS 15 14 13 12 11 10 9 8 7 6 5 4 3
APACHE II 0 1 2 3 4 5 6 7 8 9 10 11 12
 
Chronic Health Evaluation (CHE) 
One point assigned for each of the following co-morbidities (0-5 points, see original publication for definitions);  
1. Liver disease.  2. Circulation disorder.  3. Respiratory disease.  4. Renal disease.  5. Immune deficiency. 
For non operative or emergency postoperative patients +5 points 
For elective postoperative patients +2 points 
 
Age 
Age >75 65-74 55-64 45-54 <44 
APACHE II 6 5 3 2 0 
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The Pneumonia Severity Index (PSI) adopted from the original publication by Fine et al. (64) 
Step 1.   If patient is at low risk, class I (<50 years old, no history of coexisting conditions or 
abnormalities on physical examination), outpatient treatment recommended. 
Step 2.   If any condition according to step 1 is not fulfilled go to step 2. 
 
Step 2     
Characteristics     Points assigned 
Demographic factors 
 Age in years 
Male     Age 
Female     Age-10   
 Nursing home resident    +10 
Coexisting conditions   
Neoplastic disease    +30 
Liver disease     +20 
Congestive heart failure    +10  
Cerebrovascular disease    +10 
Renal disease     +10 
Physical-examination findings 
Altered mental status    +20 
Respiratory rate >30/minute    +20 
Systolic blood pressure <90 mm Hg   +20 
Temperature 350C or >400C    +15 
Pulse >125/minute    +10 
Laboratory and radiographic findings 
Arterial pH <7.35    +30 
Blood urea nitrogen >11 mmol/l    +20 
Sodium <130 mmol/l    +10 
Glucose >14 mmol/l    +10 
Haematocrit <30%    +10 
Arterial blood gas PaO2 <60 mmHg (<8 kPa) or SaO2/SpO2 <90%  +10 
Pleural effusion     +10 
Score, total points    …...  
 
 
Score Risk Class Treatment Estimated Mortality 
Step 1 none score I Outpatient 0.1% 
<70 II Outpatient 0.6% 
71-90 III Outpatient 0.9% 
91-130 IV Inpatient 9.3% 
>130 V Inpatient 27.0% 
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4 RESULTS AND DISCUSSION 
4.1 PAPER 1 
4.1.1 Underlying conditions 
A total of 460 patients with bacteraemic pneumococcal disease were prospectively 
enrolled from five centres during two years (Stockholm 290 patients, Barcelona 75 
patients, Huntington West Virginia 49 patients, Manchester 30 patients, Halifax Nova 
Scotia 16 patients). The mean, and median ages were 62 and 65 years respectively, and 
54% of the patients were male (P = 0.16). HIV-infection as well as intravenous narcotic 
use, alcoholism and liver disease were more prevalent among the Spanish patients. 
Chronic diseases were less common among the Swedish and British patients. Nursing 
home living, insulin-requiring diabetes mellitus, chronic cardiac as well as chronic lung 
diseases were more frequently seen in patients from the USA. For details see Table 1.1. 
 
4.1.2 Presentation on admission 
Pneumonia was the most common diagnosis in all five centres and occurred, as did 
meningitis, with nearly similar incidence in all centres. Mean APACHE II score was 
highest in Barcelona. However, in the remaining centres the APACHE II score was 
almost similar. ICU-admissions were also similar among the centres; however, 
mechanical ventilation was more than twice as common in Barcelona. The CFR was 
more than twice as high in Spain and in the USA, when compared with Stockholm. In 
patients with meningitis 9/34 died, and among patients diagnosed with both meningitis 
and pneumonia 5/10 died. Among patients with pneumonia who had two, or more, lung 
lobes affected 21/109 (19%) died, compared with patients who had one affected lung 
lobe where 18/245 died (7%), (P = 0.0016, Fisher´s exact test). Twelve (26%) of the 46 
patients who died from pneumonia, died within 24 hours of hospital admission, further 
details are accounted for in Table 1.1. 
 
4.1.3 Factors of prognostic importance 
Table 1.2 demonstrates factors significantly correlated to the CFR in univariate analysis 
by the Cochran-Mantel-Haenszel method. Two-thirds of deaths were recorded in 
patients more than 65 years old, and the CFR was associated with a threefold increase 
in nursing home residents. Among underlying chronic conditions pulmonary disease as 
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well as cardiac disease with heart failure were the conditions most clearly correlated to 
a high CFR. As shown in Table 1.1 a high APACHE II score was well correlated to the 
CFR. The mean APACHE II score was 12.4 in the 456 patients who had their score 
calculated. In patients with a score >12 the CFR was 21%, and with a score <12 the 
CFR was 2.6%, for details, see Table 1.2. The CFR rapidly increased in correlation 
with an increasing APACHE II score, and at a score of 28 the CFR was approximately 
50%. Mechanical ventilation, as well as nosocomial infections were well correlated to 
an increased CFR in univariate analysis, for further details, see Table 1.2. 
 
4.1.4 Comparison between centres 
Fisher´s exact test was used for univariate statistical analysis. A clear significant 
statistical difference could be demonstrated when Swedish patients were compared 
with patients from the USA regarding nursing home living, any chronic disease, 
chronic cardiac disease, chronic pulmonary disease, as well as total CFR. When the 
Swedish study centre was compared with the Spanish, the factors that differed 
significantly were: any chronic disease, chronic cardiac disease with, and without heart 
failure, chronic renal disease, APACHE II score >12, as well as the CFR, for details see 
the original paper (Table 5). 
 
4.1.5 Antibiotic therapy 
Cephalosporin therapy seemed initially by Cochran-Mantel-Haenszel univariate test to 
be significantly correlated with an increased CFR. This result was probably due to 
statistical imbalances between the different centres, as when multivariate analysis was 
performed no such difference could be observed regarding type of antibiotic treatment. 
The increase in CFR was probably due to the association between cephalosporin 
therapy and high APACHE II scores.  
 
4.1.6 Mortality predictors                                              
Multivariate analysis of prognostic factors present on admission in relation to the CFR 
revealed that age, nursing home living, chronic pulmonary disease, and a high acute 
physiology score (APS) were independent predictors of death. Prognostic factors 
associated with in-hospital mortality are demonstrated in Table 1.3.  
When adding factors occurring during hospital stay, to factors present on admission, as 
need for mechanical ventilation and nosocomial infection: age, chronic pulmonary 
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disease, high APACHE II scores, as well as mechanical ventilation were independently 
associated with mortality, see Table 1.4. 
 
4.1.7 Discussion 
Important prognostic factors determining mortality in community-acquired bacteraemic 
pneumococcal disease, in five centres, located in five different countries, were 
prospectively examined during 2 years. 
The virtually identical rate of pneumococcal meningitis cases in the different study 
centres supports the assumption that that these cases of pneumococcal bacteraemia are 
almost always admitted to hospital, have blood cultures taken, and are accurately 
diagnosed. This also supports that the indications for having blood cultures drawn are 
most probably, similar in all five sites. Other studies, where patients with bacteraemic 
pneumococcal disease were studied, have presented rates of pneumococcal meningitis 
practically identical with the results of paper 1 (34, 77-80).  Additionally, the CFR in 
paper 1 does not differ from results of previous studies (35, 41, 77, 78, 80-85), 
including as well the difference in CFR between the centres in Stockholm and 
Huntington, West Virginia (40).  
Older age, in accord with previous studies (35, 78, 80, 82, 84-88), as well as pulmonary 
disease, were independent risk factors for death. In a large meta analysis by Fine et al. 
(6), of patients with CAP of different origin, chronic pulmonary disease had no impact 
on mortality (OR. 1.0), whereas neurologic disease (OR. 4.6) as well as neoplastic 
disease (OR. 3.8) and congestive heart failure (OR. 2.4) had a clear significant 
influence on mortality. The results reported in the study by Fine et al. (6) are not 
completely in accordance with the observations made in paper 1. This may be due to 
the fact that Fine´s study included patients with CAP of different microbial aetiology, 
not only CAP caused by Streptococcus pneumoniae. 
Nursing home living; however, not smoking or alcohol abuse, were independently 
important regarding prognosis. These findings were in agreement with a study by 
Watanakunakorn, and colleagues (80). Furthermore, patients infected with HIV had a 
good prognosis, which corresponds to studies by Hibbs et al. (89), and Feldman et al. 
(90). 
As noted in two studies (78, 91), need for mechanical ventilation indicated a serious 
prognosis; however, ICU-admission without need for mechanical ventilation did not. 
An APACHE II score >14, as well as the APACHE II score component APS score >9, 
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implied an immediate rise in the CFR. Thus, both scoring systems worked very well as 
prognostic predictors of mortality. When multivariate analysis was performed (data not 
shown) APS plus age and underlying disease could not predict death as well as 
APACHE II. Therefore, a conclusion that can be drawn from this study is that the 
APACHE II scoring system can be used as the sole prognostic index for patients 
admitted with suspected bacteraemic pneumococcal disease. Two other studies have 
both concluded that an APACHE II score >15 often goes together with an increased 
CFR in patients with severe pneumonia (92), as well as bacteraemic pneumococcal 
pneumonia (80). Additionally, consistent with the findings in paper 1 is that 
radiographic extension of pneumonia well correlates with mortality, noted in previous 
studies (80, 92). 
The CFR of the study populations in the USA, and in Spain was more than twice as 
high as in Sweden. By univariate analysis factors, such as age, nursing home residency 
any chronic disease, cardiac disease, heart failure, pulmonary disease, mechanical 
ventilation, high APACHE II score, and nosocomial infections, were significantly less 
prevalent in the Swedish study populations, when compared to the studied patients 
from the USA and Spain. Though, these differences in CFR could not be confirmed 
when comparable patients from the USA, Spain, and Sweden were weighed against 
each other by multivariate statistical analysis. Difference in mortality between the study 
populations from the USA, and Sweden is in accordance with the CFR of patients in a 
previous study (40), of patients with bacteraemic pneumococcal disease. The cause or 
causes for this difference between study centres in regard to CFR, remains unexplained. 
Higher prevalence of nursing home residency, as well as underlying morbidity, may be 
of importance. 
 
4.1.8 Conclusion 
In 460 prospectively enrolled patients from five centres, in five countries, with 
bacteraemic pneumococcal disease the APACHE II score accurately and excellently 
predicted the fatality risk. Independently associated with risk of death, were: 
mechanical ventilation (OR, 4.4), nursing home living (OR, 2.8), chronic pulmonary 
disease (OR, 2.5), and age over 65 years (OR, 2.2). Two or more affected lung lobes, 
on chest x-ray, was independently associated with an increased CFR for patients who 
had pneumonia. The in-hospital CFR was significantly higher among patients treated at 
the study centres in the USA and in Spain, when compared to the patients treated at the 
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Swedish study centre. However, no independent significant factors for these differences 
were identified. 
 
Table 1.1. Demographic and clinical characteristics for 460 patients with bactearaemic pneumococcal  
disease at five study centres.      
 Stockholm Barcelona Huntington Manchester Halifax   
Characteristics Sweden Spain WV, USA UK Canada Total 
 N = 290 N = 75 N = 49 N = 30 N = 16 N = 460 
 Age median, years 66 65 65 50 66 65 
 Age mean, years 62 60 64 53 63 62 
 Male (%) 147 (51) 43 (57) 32 (65) 19 (63) 6 (38) 247 (54) 
 Nursing home (%) 15 (5) 6 (8) 7 (14) 1 (3) 3 (19) 32 (7) 
 Smoking currently (%) 90/260(51) 31/72 (41) 19 (39) 15/29  (50) 4 (25) 159/126(37) 
 Smoking recently (%) 14 (5) 9 (12) 4 (8) 4 (13) 1 (6) 32 (7) 
 Alcoholism (%) 20/274 (7) 17/73 (23) 6 (12) 3/29 (10) 1 (6) 47/441(11) 
 IV narcotics (%) 4/276 (1.5) 14 (19) 2 (4) 1/29 (3) 1 (6) 22/445 (5) 
Chronic disease       
   Cardiac 98 (34) 12 (16) 25 (51) 5 (17) 5 (31) 145 (32) 
   Cardiac+heart failure 44 (15) 2 (3) 12 (24) 2 (7) 1 (6) 61 (13) 
   Pulmonary 49 (17) 15 (20) 21 (43) 7 (23) 7 (44) 99 (22) 
   COPD 20 (7) 11 (15) 15 (31) 3 (10) 3 (19) 52 (11) 
   Liver 12 (4) 14 (19) 4 (8) 1 (3) 2 (13) 33 (7) 
   Renal 8 (3) 6 (8) 3 (6) 0 1 (6) 18 (4) 
   Diabetes mellitus 13 (4) 8 (11) 7 (14) 1 (3) 1 (6) 30 (7) 
   Active cancer 19 (7) 7 (9) 4 (8) 2 (7) 0 32 (7) 
   HIV-infection 10/211 (5) 18/72 (25) 1 (2) 0 0/15 29/376 (8) 
   Prednisolone >5        
   mg/day 15 (5) 4 (6) 6 (12) 4 (13) 2 (13) 31 (7) 
   Any chronic disease 192 (66) 63 (84) 40 (82) 17 (57) 13 (81) 325 (71) 
Diagnosis       
   Pneumonia 236 (81) 62 (83) 40 (82) 24 (80) 13 (81) 375 (82) 
   >2 lobes affected,% 30 32 41 5 38 31 
   No focus found 27 (9) 4 (5) 5 (10) 2 (7) 1 (6) 39 (8) 
   Meningitis 21 (7) 7 (9) 3 (6) 2 (7) 1 (6) 34 (7) 
   Arthritis 8 (3) 1 (1) 0 2 (7) 1 (6) 12 (3) 
   Peritonits 0 2 (3) 1 (2) 1 (3) 1 (6) 5 (1) 
   Endocarditis 0 0 0 1 (3) 0 1 (0.2) 
APACHE II score        
mean 11.6 15.3 12 13.2 13.2 12.4 
ICU-treatment 51 (18) 21 (28) 9 (18) 3 (10) 4 (25) 88 (19) 
Mechanical        
ventilation 21 (7) 19 (25) 5 (10) 3 (10) 3 (19) 51 (11) 
Died 23 (8) 15 (20) 10 (20) 4 (13) 1 (6) 53 (12) 
More than 1 disease may have been diagnosed. Number of lobes was determined in 354 patients.  
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Table 1.2. Different factors effect on CFR in 460 patients with bacteraemic 
pneumococcal disease.      
  Patients who died Prognostic influence of factor 
Factor  + factor - factor OR 95% CI P-valuea 
Age >65 years 35/224(16) 18/235 (8) 2.4 1.3 - 4.4 0.004 
Nursing home living 9/32 (28) 44/428(10) 3.2 1.4 – 7.5 0.007 
Pulmonary disease 21/99 (21) 32/359 (9) 2.6 1.4 – 4.9 0.003 
APACHE II score >12 47/222(21) 6/234 (2.6) 10.7 4.9 – 23.1 0.001 
ICU- treatment 26/88 (30) 27/372 (7) 5.3 3.0 – 9.5 0.001 
Mechanical ventilation 23/51 (45) 30/409 (7) 8.9 4.9 – 16.3 0.001 
Nosocomial infection 11/34 (32) 42/426(10) 3.7 1.7 – 8.0 0.001 
Cephalosporin      
treatment  44/276(16) 9/184 (5) 3.1 1.5 – 6.5 0.003 
aCochran-Mantel-Haenzel test.     
Data are, number of patients/ number of patients with = + or without factor = - (%) 
CFR, case fatality rate; OR, odds ratio; CI, confidence interval; ICU, intensive care unit 
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Table 1.3. Impact of admission factors associated with in-hospital mortality by 
multivariate analysis.   
Admission factor Odds Ratio 95% CI P-value 
Age >65 years 2.2 1.1-4.4 0.026 
Nursing home living 2.8 1.0-7.3 0.043 
Chronic pulmonary disease 2.5 1.2-5.1 0.014 
Acute physiology score (APS)    
 5-8 3.1 0.9-15 0.10 
 9-14 7.6 2.4-33 0.002 
 15-17 22 5.8-112 <0.0001 
 >18 41 12-194 <0.0001 
Treatment study centre, USA 2.5 0.94-6.4 0.058 
Treatment study centre, Spain 2.1 0.96-4.7 0.057 
CI, confidence interval    
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Table 1.4. Impact of admission factors plus factors occurring during hospital stay 
associated with in-hospital mortality by multivariate analysis.  
Factor Odds Ratio 95% CI P-value 
Age >65 years 2.3 1.1-5.0 0.033 
Nursing home living 2.5 0.83-6.9 0.093 
Chronic pulmonary disease 2.2 1.0-4.7 0.048 
Acute physiology score (APS)    
 5-8 2.1 0.9-1.3 0.35 
 9-14 3.6 0.73-2.2 0.14 
 15-17 6.8 1.1-5.2 0.049 
 >18 11 1.8-7.6 0.013 
Need for mechanical ventilation 4.4 1.1-22 0.045 
Nosocomial infection 1.9 0.70-5.1 0.19 
CI, confidence interval    
 
 
 
 
 
 
 
 
 
 
 
  23
4.2 PAPER 2 
4.2.1 Underlying conditions 
From paper one 370 patients with bacteraemic pneumococcal pneumonia were 
retrospectively analysed in this paper. Of the 370 patients enrolled in the first paper, 
340 received a β-lactam antibiotic, with or without the addition of a macrolide 
antibiotic. Table 2.1 demonstrates the demographic characteristics, and Table 2.2 the 
clinical characteristics of the 261 patients who received a β-lactam without a macrolide 
(M-), and of the 79 patients who received a β-lactam plus a macrolide (M+). Univariate 
statistical analysis revealed no difference regarding time to admission, age, smoking 
alcohol abuse, gender, cardiac disease with heart failure, pulmonary disease as well as 
chronic obstructive pulmonary disease (COPD) between the M+ and M- patients. 
However, intravenous drug abuse, cardiac disease except heart failure, and liver disease 
were more common among the M+ patients, for further details see Tables 2.1 and 2.2. 
 
4.2.2 Presentation on admission 
The APACHE II score as well as the APS were significantly higher in the M+ patients. 
Need for ICU-therapy did not differ between the two groups while a higher proportion 
of M+ patients required mechanical ventilation. 
 
4.2.3 Antibiotic therapy, mortality, and mortality predictors 
In-hospital CFR among the M+ patients was 19.0%, and among the M- patients 10.7%. 
The difference in CFR between the two groups was not statistically significant (P = 
0.08). Clinical characteristics of the M-, and M+ patients are presented in Table 2.2. As 
antibiotic therapy may not have had the time to alter the CFR in the 13 patients who 
died within two days of hospital arrival, statistical analysis without these patients was 
performed, as was statistical analysis performed in the severely ill patients with 
APACHE II score >12. Patients who for initial antibiotic treatment only received one 
single β-lactam-antibiotic, with or without the addition of a macrolide, were as well 
analysed separately. No significant difference in CFR was noted between the different 
groups of M-, and M+ patients, when statistical analysis was performed, for details, see 
Table 2.3. We also examined if CFR varied between the different study years, or if 
CFR changed when only patients aged over 50 years were included in the statistical 
analysis. However, no differences between the two groups were discerned. 
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4.2.4 Mortality predictors 
By use of a logistic regression model for statistical analysis we tested factors 
independently associated with the CFR such as age, APS for estimating disease 
severity, two or more lung lobes affected according to chest x-ray, chronic lung disease. 
We included β-lactam-macrolide combination treatment in this model. No significant 
reduction in CFR was observed with the addition of this antibiotic regimen, details are 
demonstrated in Table 2.4. 
 
4.2.5 Discussion 
Several studies (44, 93-95) have demonstrated a decreased CFR in patients with 
community acquired bacteraemic pneumococcal pneumonia who have received a 
combination of β-lactam and macrolide antibiotics for initial antibiotic treatment. In 
one study (44) a reduction of the CFR was observed in retrospectively analysed adult 
patients older than 50 years, collected in one American city between1978 and 1997. 
Moreover, in another study (93) where patients had been included during a ten-year 
period multivariate, but not univariate, statistical analysis showed that when initial 
antibiotic treatment included a macrolide agent, CFR was reduced. In a prospective 
observational study (95) the CFR was reduced in the 16% of the patients classified as 
“critically ill” who received any combination of two or more antibiotics. 
In the present study we were not able to find a reduction in CFR among patients who 
received antibiotic combination therapy with a β-lactam and a macrolide. On the 
contrary univariate statistical analysis revealed a trend towards an increased CFR in 
patients who received antibiotic combination therapy. However, when previously 
independent risk factors for death such as age, nursing home living, chronic pulmonary 
disease, APS, and >2 affected lung lobes were included in a multivariate statistical 
regression model, no difference was observed regarding the use of different antibiotic 
treatment regimens. When statistical analysis was restricted to patients more than 50 
years of age, severely sick patients, or those patients who survived two days after 
admission, no difference in CFR could be observed, regardless of the initial antibiotic 
regimen - β-lactam antibiotic therapy, with or without the addition of a macrolide. 
Several explanations have been proposed for a mortality reduction in patients with 
bacteraemic pneumococcal pneumonia who receive antibiotic combination therapy -  
difference in killing rates by different antibiotics, bacterial pathogen tolerant to one 
antibiotic, co-infection with atypical microbiological agents such as Legionella species, 
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antimicrobial synergism, macrolide antibiotic effect on cytokine production, as well as 
effect on pneumococcal adherence to respiratory epithelial cells (48, 51, 52). However, 
the impact, of the above listed proposed explanations, has not yet been proved to be of 
clinical importance. In a mouse peritonitis model, as well as in vitro, antagonism or 
indifference, instead of synergism, was found between a macrolide antibiotic 
(erythromycin) and β-lactam (penicillin, cefotaxime) (53, 54). 
There is still need for prospective randomised studies regarding the issue whether 
antibiotic combination therapy with a β-lactam and a macrolide is beneficial for 
patients with severe pneumococcal pneumonia. Excessive use of combination therapy 
in patients with suspected, or proven, bacteraemic pneumococcal pneumonia, risk to 
increase costs, adverse effects, as well as resistance to antibiotics. 
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Table 2.1. Demographic characteristics of the 340 patients with bacteraemic pneumococcal 
pneumonia that received ß-lactam antibiotics alone (M-), or combined with a macrolide (M+). 
  M- M+  
Characteristics  N=261 N=79 P-valueb 
Age, years     
  median  66 60 0.069 
  mean  63.0 58.5  
Malea  136 (52.1) 45 (57.0) 0.520 
Nursing home livinga 21 (8.0) 5 (6.3) 0.810 
Smokinga     
Currentlya  89 (34.1) 35 (44.3) 0.110 
Recentlya  20 (7.7) 5 (6.3) 0.810 
Alcoholisma  24 (9.2) 12 (15.2) 0.145 
IV drug abusea 7 (2.7) 7 (8.9) 0.013 
Chronic disease     
  cardiaca  93 (35.6) 16 (20.2) 0.013 
  cardiac with heart failurea 43 (16.5) 6 (7.6) 0.066 
  pulmonarya  53 (20.3) 24 (30.4) 0.067 
  obstructive pulmonary diseasea 27 (10.3) 15 (19.0) 0.051 
  livera  14 (5.4) 10 (12.7) 0.042 
  renala  10 (3.8) 1 (1.3) 0.468 
  insulin-treated diabetesa 16 (6.1) 7 (8.9) 0.443 
  active cancera  17 (6.5) 3 (3.8) 0.585 
  HIV-infectiona  14 (5.4) 7 (8.9) 0.286 
Therapy >5 mg prednisolon/daya 15 (5.8) 3 (3.8) 0.774 
ano. of patients (%)    
bdifference between groups M- and M+, Fisher's exact test for binary variables and the 
Wilcoxon rank sum test for continuous variables   
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Table 2.2. Clinical characteristics of the 340 patients with bacteraemic pneumococcal 
pneumonia that received ß-lactam antibiotics alone (M-), or in combination with a 
macrolide (M+).    
  M- M+  
Characteristics  N=261 N=79 P-valueb 
Days to admission    
   median  3 3 0.293 
   mean  3,6 4,2  
>2 lobes affecteda 72 (27.6) 32 (40.5) 0.363 
APACHE II score    
median  11 13 0.022 
mean  12.1 13.8  
Acute Physiology Score APS    
median  6 8,5 0.0002 
mean  7.4 9.6  
ICU treatmenta  40 (15.3) 15 (19.0) 0.486 
mechanical ventilationa 20 (7.7) 13 (16.5) 0.029 
nosocomial infectiona 20 (7.7) 6 (7.6) 1.00 
Dieda  28 (10.7) 15 (19.0) 0.080 
ano. of patients (%)    
bFisher's exact test for binary variables and Wilcoxon rank sum test for continuous 
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Table 2.3. Case fatality rate in patients receiving ß-lactam alone (M-), or in 
combination with a macrolide (M+) for initial therapy.   
Antibiotic options  M- M+ P-valuea 
All patients   28/261(10.7) 15/79 (19.0) 0.080 
Excluding 13 patients who died    
within 2 days of admission  21/254 (8.3) 9/73 (12.3) 0.336 
Patients with APACHE II score >12 25/117(21.4) 15/48 (31.2) 0.230 
Patients with APACHE II score >12,    
excluding 12 patients who died within    
2 days of admission  19/111(17.1) 9/42 (21.4) 0.640 
Patients with APACHE II score >19 13/34 (38.2) 9/17 (52.9) 0.378 
Patients with APACHE II score >19,    
excluding 9 patients who died within 2     
days of admission  9/34 (30.0) 4/12 (33.3) 1.00 
aFishers exact test     
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Table 2.4. Multivariate analysis of factors of possible independent importance for the 
risk of death in 340 patients with bacteraemic pneumococcal pneumonia. 
Factors  OR 95% CI P-valuea 
Aged >65 years 2.57 1.18 - 5.86 0.020 
Nursing home living 2.53 0.786 - 7.55 0.104 
Chronic pulmonary disease 1.89 0.797 - 4.40 0.141 
>2 lung lobes affected 2.17 1.01 - 4.67 0.045 
APS 5-8  3.94 0.894 - 27.4 0.098 
APS 8-14  8.26 2.13 - 54.8 0.007 
APS 14-17  23.8 4.77 - 180.3 0.0004 
APS >18  53.8 11.8 - 395.0 <0.0001 
Addition of a macrolide 1.09 0.414 - 2.70 0.844 
APS, acute physiology score (i.e., APACHE II without age and chronic disease scores); 
OR, odds ratio; CI, confidence interval  
ap-value testing the null hypothesis OR=1, OR estimate and two-sided 95% confidence  
interval for OR, multiple logistic regression analysis  
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4.3 PAPER 3 & 4 
4.3.1 Underlying conditions  
Univariate statistical analysis of the 375 patients in paper 3, who all suffered from 
bacteraemic pneumococcal CAP, revealed that older age, underlying medical 
conditions such as cerebrovascular and renal disease, as well as >1 coexisting disease 
defined according to the PSI-rule (in Table 3.1 called D) were significantly associated 
with an increased risk of death. Clinical and demographic data on patients are 
demonstrated in Table 3.1.  
Among the 1172 patients, with CAP of different microbial aetiology, described in 
paper 4, older age, male sex, nursing home living, atherosclerotic heart disease, heart 
failure and any cardiac disease, cerebrovascular, renal and malignant disease were all 
conditions significantly associated with an increased CFR. For details of the univariate 
statistical analysis of clinical and demographic data, see Table 4.1. 
 
4.3.2 Presentation on admission 
In paper 3 associated with a statistically significant increase in CFR were altered 
mental status, respiratory rate >30/minute, measured by arterial blood gas analysis pH 
<7.35, serum creatinine >130 µmol/l, peripheral oxygen saturation <90% (abbreviated 
as SaO2 in paper 3 and SpO2 in paper 4), PaO2 <8 kPa (<60 mmHg) measured by 
arterial blood gas analysis, need for ICU-treatment, mechanical ventilation, and number 
of lung lobes affected (visualised by chest x-ray or chest CT), for details, see Table 3.2. 
In paper 4 a significant increase in CFR, was observed, as in paper 3, for altered mental 
status, respiratory rate >30/minute, pH <7.35, serum creatinine >130 µmol/l, need for 
ICU-treatment, and ventilator support. Furthermore in paper 4 a low blood pressure 
(systolic <90 mmHg, or diastolic <60 mmHg), SpO2 <90%, and non-invasive 
ventilation (NIV) were all factors associated with increased mortality, see Table 4.2 for 
details. 
 
4.3.3 Prognostic importance of severity criteria in relation to 30-day mortality 
Table 3.4.3 demonstrates (paper 3, and paper 4) cut off values, sensitivity, specificity, 
positive and negative predictive values for CRB-65, as well as for the modified CRB-
65 (DS CRB-65) in relation to 30-day mortality. We let the existence of one, or more, 
of the diseases (D) that are part of the PSI-score, add an extra point to the modified 
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CRB-65 score. If poor oxygenation (S) was noted, we also let this finding yield an extra 
point to the modified CRB-65. The accuracy of this modified score, DS CRB-65, is 
demonstrated in Table 3.4.3. In paper 3, 97/375 (26%) of the patients received score 0 
(3 deaths), thus classified as low risk by CRB-65. In paper 4 were 376/1172 (32%) of 
the patients similarly classified (1 death). If, by use of DS CRB-65, score 0-1, in paper 
3, would be defined as low risk 166/375 (44%) of the patients would be included (5 
deaths), and with the same score would 596/1172 (51%) of the patients in paper 4 be so 
defined (2 deaths). If DS CRB-65 score <2 would define low risk in paper 3, 264/375 
(70%) of the patients would be included (7 deaths). In paper 4, DS CRB-65 score <2 
would include 835/1172 (71%) of the patients with 14/835 (2%) recorded deaths, 18% 
of all patients who died in paper 4.The AUC of the ROC curve for CRB-65, as well as 
DS CRB-65 in paper 3 (Fig 1) was 0.77 (CI 0.66-0.84), and 0.83 (CI 0.73-0.89), P = 
0.01 for the difference. In paper 4 the AUC of the respective ROC curve for CRB-65, 
and DS CRB-65 (Fig 2) was 0.82 (CI 0.77-0.85), and 0.87 (CI 0.84-0.90), P <0.0001 
for the difference. The ROC curves AUCs, Z-values, and confidence intervals for the 
different scoring systems are demonstrated in Table 3.4.4. For DS CRB-65 the Youden 
Index was applied to find an accurate cut off score for predicting 30-day mortality in 
paper 4. For score >3 (sensitivity 82%, specificity 75%) the highest value was 
calculated, 0.58. The second highest value, 0.52, was calculated for score >2 
(sensitivity 98%, specificity 54%). Notably, score 0-1 identified 51% of patients as at 
low risk, with a mortality of 0.3% (2 deaths). 
 
4.3.4 Discussion 
When treating a patient with suspected or proven CAP the physician often has to decide 
whether the patient should be admitted for hospital treatment, or could be safely treated 
at home. If the patient can be treated at home, on an outpatient basis, costs are reduced, 
and risk for nosocomial infections are eliminated. In a study by Coley et al. (96) were 
patients who received outpatient treatment able to resume normal activity sooner than 
patients who were hospitalised. Severity scoring systems for patients with CAP may 
facilitate the site of care decision. The PSI is the most thoroughly evaluated severity 
scoring system for patients with low-risk CAP suitable for outpatient management (64, 
65, 97). However, the PSI is rather cumbersome and time consuming to use, as 20 
parameters with different weight are included. Though, the PSI was developed and 
advocated in North America (97), CURB-65 is now recommended by the Infectious 
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Diseases Society of America and the American Thoracic Society (98). As a laboratory 
parameter, urea, is included in CURB-65, the result of a laboratory analysis has to be 
awaited before the site of care decision can be made. CRB-65, originally advocated for 
use in outpatient settings, does not require results of any laboratory test. The CRB-65 
has been studied in over 6000 patients (63), seen both in community and in hospitals, 
and is widely used in European countries. The Swedish Society of Infectious Diseases 
(Svenska Infektionsläkarföreningen) recommends that CRB-65 should be used to 
assess mortality risk in patients with CAP, since it has the advantage of not requiring 
venous blood samples (42).  
When the PSI was developed underlying medical conditions (malignancy, liver disease, 
cerebrovascular disease, renal disease, and congestive heart disease), as well as low 
partial pressure of oxygen, or low oxygen saturation, were found to be independently 
associated with an increased mortality risk. Information regarding underlying medical 
conditions, as well as level of peripheral oxygen saturation by pulse oximetry (SpO2), 
can easily be obtained in the ED.  
For the prognosis of CAP the importance of underlying medical conditions are in 
accordance with several recent studies (38, 72, 99-101), and can probably partly be 
explained by the independent prognostic importance of high urea and low serum 
albumin found in other studies (61, 62, 101, 102). In recent reports poor oxygenation 
has proved to be of independent prognostic importance in proposed new scoring 
systems, as A-DROP (70), SMART-COP (71), and SCAP (72). These recently 
described severity scoring systems for patients with CAP seem to perform as well, or 
even better, than previous systems used for assessing severity of patients with CAP. 
However these scoring systems are not independent of laboratory resources. The Pitt 
bacteraemia score, as well as the modified American Thoracic Society score have been 
found to be the most accurate scores for identifying need for ICU treatment in patients 
with bacteraemic pneumococcal pneumonia (103). However, in both scores the need 
for mechanical ventilation and septic shock are included (both conditions in most cases 
indications for referral to the ICU), so the indication for critical care would be 
expected.  Moreover, none of these two studies are aimed to identify patients in the ED 
who could be suitable for outpatient treatment. 
In paper 3 and in paper 4 our aim was to analyse the accuracy of a modified CRB-65 
scoring system in patients with CAP. We found in paper 3, in accordance with previous 
results when the PSI scoring system has been employed (97), that the presence of one 
or more of the following conditions - malignant, hepatic, renal, cerebrovascular disease, 
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and cardiac failure, were independently associated with 30-day mortality. The 
calculations were simplified by letting the existence of one, or more, of these 
conditions increase the sum of the “DS CRB-65” with 1 point. In accordance with the 
PSI we found as well that independently associated with 30-day mortality was the 
presence of hypoxaemia (PaO2 <8 kPa measured by arterial blood gas, or a peripheral 
oxygen saturation <90% measured by pulse oximetry). Other combinations of 
underlying diseases, or clinical parameters were tested, but did not improve the 
accuracy of the modified CRB-65. 
ROC curves for CRB-65, and DS CRB-65 were constructed for the endpoint 30-day 
mortality. When the AUCs of the different ROC curves were compared for patients 
with bacteraemic pneumococcal CAP (paper 3), and patients with CAP of different 
aetiology (paper 4) a clear statistical significant difference between the scoring systems 
was observed (P = 0,01 in paper 3, and P <0.0001 in paper 4). For patients classified as 
at low risk of dying within 30 days of admission (for CRB-65, score 0, for DS CRB-65, 
score 0-1) both CRB-65 (paper 3, three deaths, paper 4, one death), and DS CRB-65 
(paper 3. five deaths, paper 4, two deaths), had a satisfactory prognostic accuracy. 
However, in paper 4, CRB-65 classified only 32% of the patients as at low risk of 
death, while with DS CRB-65 51% of the patients could be so classified, while 
retaining a low CFR (0.3%). Thus, DS CRB-65 may be a more useful prognostic tool 
than CRB-65, while keeping its independency of laboratory tests. 
Paper 3 and paper 4 were both retrospectively designed. In paper 3 only patients with 
bacteraemic pneumococcal CAP were included, However, Streptococcus pneumonia is 
the leading cause of bacterial CAP, as well as the leading cause of death due to CAP 
(104, 105). The CFR among the patients in papers 3 and 4 was almost similar, 9%, 
though the patients in paper 4 were unselected and suffered from CAP of different 
microbial origin. Thus, it seems possible that a majority of the patients in paper 4 who 
died suffered from CAP due to Streptococcus pneumonia, as it is the most commonly 
occurring pathogen in CAP, as well as it is the leading cause of death in CAP (6).  
In paper 3 patients were enrolled during two time-periods 1993-1995, 1999-2000. It 
may be questioned whether results from a study that took place nearly 20 years ago can 
be relevant today? However, in paper 3 all patients who were included in the study, 
were diagnosed by identical criteria: Streptococcus pneumoniae bacteraemia, new 
radiographic finding consistent with pneumonia, hospital admission, and use of 
identical CRFs. As patients were enrolled during two periods of time we compared the 
data from an on-going surveillance study of invasive pneumococcal disease in Sweden 
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to assess the generalisability of paper 3. Since 2006 it has been mandatory to report all 
cases of invasive pneumococcal disease in Sweden to the Swedish Institute for 
Infectious Diseases Control (Smittskyddsinstitutet, SMI). From January 2007 through 
December 2009, questionnaires regarding clinical information about patients with 
detected bacteraemic pneumococcal disease were returned from clinicians in charge at 
sites with notified bacteraemic pneumococcal disease. Of these 529 reported patients, 
430 patients had pneumonia, and 46 of these patients died (CFR 11%) within 30 days 
after blood culture samples were taken. As the CFRs in paper 3 were almost similar in 
patients enrolled during the years 1993-1995, 1999-2000, as well as in the on-going 
study at the Swedish Institute for Infectious Diseases Control, and in previous Swedish 
studies of patients with pneumococcal bacteraemic CAP (37, 38, 40), we do not believe 
that, though patients were recruited during the years 1993 to 1995, this has had any 
significant influence on the results in paper 3. 
In both papers serum creatinine replaced serum urea, a modification that is in 
accordance with previous studies, and ATS guidelines (38, 106).  
In paper 4, patients with CAP of different microbial aetiology were studied, and 
patients admitted to hospital, as well as patients treated on outpatient basis were 
included. All hospitalised patients had a new finding on chest x-ray or chest CT 
consistent with pneumonia. In 144 of the 342 (42%) patients treated as outpatients, no 
chest x-ray, or chest CT, was performed and two of these patients died within 30 days. 
However, as a clear majority of the patients in paper 4 had radiographic findings 
compatible with pneumonia, revealed by chest x-ray, or CT, and as 94% of all patients 
who died were admitted for hospital care, missing radiological examination could 
hardly have affected the comparison between CRB-65 and DS CRB-65, which was the 
main objective of this study. Moreover, the way patients were examined, assessed and 
finally diagnosed with CAP, without chest radiography, is part of how CAP-patients 
who do not need hospitalisation are handled in the ED. Lack of roentgen examination 
in 144 of the ambulatory treated patients may have had an impact on the calculation of 
the PSI score, as the finding of pleural effusion increase the PSI score by 10 points. 
However, the main objective of the study described in paper 4, was to compare CRB-
65 with DS CRB-65 in patients with CAP. 
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4.3.5 Conclusion 
Paper 3, and paper 4 indicate that by adding data on the existence of underlying health 
conditions, as well as the presence of hypoxaemia in patients with CAP, the 
uncomplicated prognostic score CRB-65 will improve its accuracy and precision in 
predicting 30-day mortality, while retaining its independence of laboratory tests. The 
improved score, DS CRB-65, can easily be used in the ED, as well as outside the 
hospital to facilitate the site of care decision for a patient with suspected CAP. New 
studies, preferably prospective, as well as re-analysis of data from previous studies are 
needed to further evaluate, and confirm, the role of DS CRB-65 as a scoring system for 
early risk assessment of patients with CAP. 
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Table 3.1. Clinical and demographic data for patients who survived and for those whoa 
died. Paper 3.     
  Survived  Died  
Characteristics  N=340  N=35 P-value 
Age, years      
  medianc  62.0  75.0 0.002 
  mean  60.6  70.3  
  range  18-98  38-93  
Femaleb  173 (51)  13 (37) 0.1 
Nursing home livingb 9 (3)  3 (9) 0.09 
Smoking      
  currentlyb  117 (34)  9 (26) 0.4 
  recentlyb  13 (4)  2 (6) 0.6 
Alcoholismb  30 (9)  7 (20) 0.06 
IV drug abuseb  10 (3)  2 (6) 0.3 
Cardiac disease      
  cardiac anyb  98 (29)  14 (40) 0.2 
  heart failureb  48 (14)  7 (20) 0.6 
  hypertensionb  33 (10)  6 (17) 0.2 
  atherosclerotic  63 (18)  7 (20) 0.8 
Chronic disease      
  cerebrovascular  11 (3)  4 (11) 0.04 
  pulmonaryb  59 (17)  5 (14) 0.8 
  liverb  22 (6)  5 (14) 0.09 
  renalb  4 (1)  3 (9) 0.02 
  diabetesb  28 (8)  5 (14) 0.2 
  malignancyb  23 (7)  4 (11) 0.3 
  HIVb  13 (4)  1 (3) 1.0 
  immunosuppressionb 25 (7)  4 (11) 0.3 
Preexisting diseases ”D” b 93 (27)  18 (51) 0.006 
Any other preexisting diseasesb 183 (53)  25 (71) 0.05 
aNo. (%). bFisher´s exact test used. cWilcoxon/Kruskal-Wallis rank sum test used.  
Preexisting disease, ”D”,coexisting disease defined according to the PSI rule – malignant disease, liver 
disease, congestive heart failure, cerebrovascular disease, renal disease. 
Any other preexisting disease, ”D” plus chronic lung disease (obstructive, restrictive e t c), diabetes 
mellitus (insulin and non-insulin dependent), chronic heart disease(congestive, atherosclerotic, 
hypertensive, valvular, arrythmic e t c). 
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Table 3.2. Physical examination, laboratory findings and ICU-treatment in patients  
who survived, and in patients who dieda. Paper 3.   
  Survived  Died  
  N = 340  N = 35  
Findings  N (%)  N (%) P-value 
      
Altered mental staus 34 (10)  16 (46) <0.0001 
Respiratory rate >30/mina 86 (25)  19 (54) 0.0006 
Systolic BP <90 mmHg or     
diastolic BP <60 mmHga 95 (28)  13 (37) 0.2 
Body temperature     
<35 or >40°Ca 23 (7)  2 (6) 1.0 
Pulse >125a  56 (16)  10 (29) 0.1 
pH <7.35a  13 (4)  11 (31) <0.0001 
Creatinine  >130 µmol/la 85 (25)  25 (71) <0.0001 
Sodium  <130 mmol/la 48 (14)  7 (20) 0.3 
Glucose   >14 mmol/la 19 (6)  3 (9) 0.4 
Haematocrit <30%     
or Hb <100 g/la 25 (7)  6 (17) 0.06 
Pleural effusiona 72 (21)  8 (23) 0.8 
SaO2 <90% or      
PaO2 <60 mmHga (8 kPa) 92 (27)  25 (71) <0.0001 
ICU-treatmenta 54 (16)  19 (54) <0.0001 
Ventilatora  17 (5)  15 (43) <0.0001 
Affected lung lobesb     
 median 1.0  2.0  
 mean 1.4  2.0 0.001 
Data are presented as No. total (%).    
ICU, Intensive Care Unit PSI; Pneumonia Severity Index; BP, blood pressure. 
aFisher´s exact test used, bt-test used    
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Table 4.1. Clinical and demographic data for patients who survived, and for those who  
died. Paper 4.     
  Survived Died  
Characteristics  N= 1092 N=80 P-valuea 
     
Age, years     
   Median  66.0 82.5 <0.0001 
   Mean  63.7 80.3  
   Range  18-100 45-99  
Male, n (%)  532 (49) 49 (61) 0.04 
Nursing home residence, 11 (1) 9 (11) <0.0001 
n (%)     
Cardiac disease, n (%)    
   Hypertensive  287 (26) 25 (31) 0.4 
   Atherosclerotic 165 (15) 20 (20) 0.02 
   Heart failure  112 (10) 31 (39) <0.0001 
   Cardiac anyb  481 (44) 53 (66) 0.0002 
Chronic disease, n (%)    
   Cerebrovascular 119 (11) 25 (31) <0.0001 
   Pulmonary  296 (27) 23 (29) 0.8 
   Liver  35 (3) 1 (1) 0.5 
   Renal  76 (7) 17 (21) <0.0001 
   Diabetes mellitus 136 (12) 15 (19) 0.1 
   Malignancy  66 (6) 10 (12) 0.03 
   HIV  11 (1) 0 1 
aFisher´s exact test was used, except for continuous data, as age, where the 
Wilcoxon/Kruskal-Wallis rank sum test was used. 
bCardiac any = hypertensive, atherosclerotic, congestive, valvular, arrhythmic e t c 
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Table 4.2. Physical examination, laboratory findings and ICU-treatment in patients  
who survived, and in patients who died. Paper 4.   
  Survived,  Died  
Findings  N=1092, N (%) N=80, N (%) P-valuea 
Altered mental status 53 (5) 14 (18) <0.0001 
Respiratory rate >30/min 229 (21) 45 (56) <0.0001 
Systolic BP <90 mmHg     
+/-diastolic BP <60 mmHg 149 (4) 31 (39) <0.0001 
Body temp. <35o or >40oC 26 (2) 3 (4) 0.4 
Pulse >125/min 67 (6) 18 (22) <0.0001 
pH <7.35  34 (3) 9 (11) 0.002 
Serum creatinine >130 µmol/lb  123 (11) 34 (42) <0.0001 
Serum sodium <130 mmol/l 30 (3) 2 (3) 1 
Serum glucose >14 mmol/l 47 (4) 6 (8) 0.2 
Hb <100 g /l  20 (2) 3 (4) 0.2 
SpO2 <90%  323 (30) 62 (78) <0.0001 
ICU-treatmentb  67 (9) 14 (19) 0.01 
Ventilatorb, c  12 (2) 5 (7) 0.01 
NIVb, d 23 (3) 9 (12) 0.001 
BP, blood pressure; Hb, haemoglobin; ICU, intensive care unit; SpO2, peripheral  
oxygen saturation measured by pulse oxymetri   
aFishers´s exact test.    
bOnly the 830 patients who were admitted were analysed.  
cVentilator = ventilatory support with patient intubated or tracheostomised. 
dNIV = non-invasive ventilatory support with patient not intubated or tracheostomised. 
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Table 3.4.3. Sensitivity, specificity, positive and negative predictive values of 30-day  
CFR of the different prediction rulesa in paper 3 and in paper 4.  
30-day CFR Cut-off Sensitivity Specificity PPV NPV 
CRB-65, paper 3      
0 3/97 (3) >0 100 0 9 NA 
1 6/140 (4) >1b 91 28 12 97 
2 10/100 (10) >2 74 67 19 96 
3 14/36 (39)  >3 46 94 42 94 
4 2/2 (100) 4 6 100 100 90 
CRB-65, paper 4      
0 1/376 (0) >0 100 0 7 NA 
1 18/471 (4) >1b 99 34 10 100 
2 35 247 (14) >2 76 76 19 98 
3 24/74 (32) >3 32 95 33 95 
4 2/4 (50) 4 2 100 50 93 
DS CRB-65, paper 3      
0 0/65 (0) >0 100 0 9 NA 
1 5/101 (5) >1 100 19 11 100 
2 2/98 (2) >2 86 47 14 97 
3 9/67 (13) >3 80 76 25 97 
4 11/32 (34) >4 54 93 43 95 
5 8/12 (67) >5 23 99 67 92 
6 0/0 6 NA NA NA NA 
DS CRB-65, paper 4      
0 0/295 (0) >0 100 0 7 NA 
1 2/301 (1) >1 100 27 9 100 
2 12/239 (5) >2 98 54 14 100 
3 19/195 (10) >3 82 75 20 98 
4 30/106 (28) >4 59 91 33 97 
5 16/34 (47) >5 21 98 47 94 
6 1/2 (50) 6 1 100 50 93 
aData are presented as No. total (%).    
PPV, positive predictive value; NPV, negative predictive value; NA, not applicable. 
CFR, case fatality rate. 
bCut-off points accepted as threshold to define high-risk groups according to original  
study design. (62, 63)      
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Table 3.4.4. Results of receiver operating characteristic (ROC) curves, of severity  
scores, in association with 30-day mortality for paper 3, and paper 4.  
 AUC SE Z-valuea  95% CI 
PSI Classb 0.84 0.03 11.3 0.77 – 0.89 
CURB-65b 0.81 0.04 8.4 0.73 – 0.87 
CRB-65b 0.77 0.05 5.8 0.66 – 0.84 
DS CRB-65b 0.83 0.04 8.4 0.73 – 0.89 
PSI Classc 0.84 0.02 19.6 0.80 – 0.87 
CURB-65c 0.83 0.02 15.8 0.79 – 0.87 
CRB-65c 0.82 0.02 15.4 0.77 – 0.85 
DS CRB-65c 0.87 0.02 22.6 0.84 – 0.90 
ato test AUC >0.5    
bPaper 3   
cPaper 4  
AUC, area under curve; SE, standard error; CI, confidence interval.  
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Figure 1. Comparative receiver operating characteristic (ROC) curves for severity 
scores CRB-65 and DS CRB-65 in association with 30-day mortality. Paper 3. For 
details, see Table 3.4.4. 
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Figure 2. Comparative receiver operating characteristic (ROC) curves for severity 
scores CRB-65 and DS CRB-65 in association with 30-day mortality. Paper 4. For 
details, see Table 3.4.4. 
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5 GENERAL SUMMARY AND DISCUSSION 
The first paper was a two-year prospective multicentre study that included 460 patients 
with community acquired bacteraemic pneumococcal disease from five centres, in five 
countries. The main aim of the study was to define prognostic factors that contribute to 
in-hospital mortality, as well as to analyse underlying and prognostic factors that may 
affect outcome in patients with bacteraemic pneumococcal disease. The scoring system 
APACHE II, a severity of disease classification system, often used in ICUs, predicted 
in-hospital CFR excellently and accurately. Independent risk factors for death, present 
on admission to hospital by multivariate analysis, were living in a nursing home, 
presence of chronic pulmonary disease, age over 65 years. Need for mechanical 
ventilation during hospital stay, was as well, a mortality risk factor found by 
multivariate analysis. Patients with pneumonia who had more than one lung lobe 
affected, revealed by chest x-ray, ran as well a significantly increased risk of death 
during hospital stay. Incidence of pneumonia and meningitis was almost similar 
between the participating centres. However, there was a great difference regarding the 
fatality rates. In the USA and in Spain, 20% of the studied patients died, while in 
Sweden 8% of the participating patients died. This significant difference in mortality 
between patients with bacteraemic pneumococcal pneumonia was demonstrated in a 
previous study (40). No plausible explanations for this difference between the 
participating centres were found. Interestingly, in paper 1, factors that were statistically 
significant regarding risk of death revealed by univariate, though not by multivariate, 
statistical analysis, such as old age, nursing home living, and heart failure, are 
prognostic factors included in the pneumonia severity index, created by Fine and 
colleagues (6). Age >65 years, revealed by both univariate and multivariate statistical 
analysis to be an important prognostic risk factor, is included in the recommended 
scoring systems for the assessment of CAP, CURB-65 and CRB-65 (62). 
In paper 2 prospectively collected data on 340 patients with bacteraemic pneumococcal 
pneumonia were studied. Patients in paper 2 participated in the multicentre study 
described in paper 1. The aim of the study was to investigate if the addition of a 
macrolide antibiotic to a ß-lactam for initial antibiotic treatment could improve in-
hospital survival. Neither univariate, nor multivariate statistical analysis could detect 
any significant decrease in CFR among patients who received antibiotic combination-
therapy, not even when taking into consideration age, severity of illness or early deaths 
could any difference be discerned.  
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The aim of the studies described in paper 3 and in paper 4 was to improve the accuracy 
of the scoring system CRB-65 as a prognostic tool to predict 30-day mortality in 
patients with bacteraemic pneumococcal pneumonia (paper 3), as well as in patients 
with pneumonia of different microbiological aetiologies. An additional purpose of the 
study (paper 4) was to find a suitable scoring point level to facilitate the decision which 
CAP patients who might safely be treated as outpatients, or benefit from inpatient care. 
Paper 3 included 375 hospitalised Swedish patients. In paper 4 a total of 1172 patients 
(830 inpatients, 342 outpatients) with pneumonia of different aetiologies were 
retrospectively enrolled during 16 months, from one teaching hospital in Stockholm, 
Sweden. By letting the existence, of one or more of the underlying medical conditions, 
that are an important part of the PSI, increase CRB-65 with one point as well as letting 
hypoxaemia, in accordance with the PSI, also increase CRB-65 with one point, we 
could design a scoring system that could easily be managed without any need for 
laboratory tests or results. We choose to call this scoring system DS CRB-65 (D for 
disease, S for oxygen saturation). From the data in paper 3 and in paper 4 ROC curves 
were constructed for the outcome, death within 30 days of hospital admission, and a 
clear significant statistical difference was observed between the AUCs of the two 
scoring systems, in favour of DS CRB-65 (P = 0.01, and P <0.0001, respectively). To 
find an appropriate cut off value for DS CRB-65 the Youden Index was applied. For 
score >3 (sensitivity 82%, specificity 75%) the highest value was calculated, 0.58. For 
score >2 (sensitivity 98%, specificity 54%) the second highest value, 0.52, was 
calculated. DS CRB-65, score 0-1, identified half of the patients in paper 4, as at low 
risk with 2 deaths (CFR, 0.3%), while among the 20% of the patients with score 2, the 
CRF had risen to 5%. 
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6 CONCLUSIONS 
The APACHE II score worked exceptionally well and accurately as a prognostic 
instrument for predicting mortality risk in patients with bacteraemic pneumococcal 
disease. In-hospital mortality differed considerably between the centres, and was more 
than twice as high in the USA and in Spain when compared to Sweden. Independent 
predictors of death present on hospital admission were age over 65 years, nursing home 
residency, presence of chronic pulmonary disease, and a high APACHE II score. Risk 
factor for death after hospital admission was need for mechanical ventilation.  Patients 
with pneumonia who on chest x-ray had two, or more, lung lobes affected, also had a 
significantly increased case fatality risk. 
When ß-lactam and macrolide antibiotics were combined for initial antibiotic treatment 
in patients with bacteraemic pneumococcal pneumonia, no in-hospital decrease in CFR 
could be observed among all participating patients, or in different subgroups of patients 
(survived first 2 days of hospitalisation, high APACHE II score on hospital admission, 
50 years of age or older, received ß-lactam and macrolide antibiotics only). 
The accuracy of CRB-65 as a prognostic tool for the prediction of mortality within 30 
days of hospital admission was significantly enhanced when underlying diseases, as 
well as hypoxaemia, both in accord with the PSI-rule, were added to the scoring 
system. The proposed new scoring system DS CRB-65 performed excellently well in 
patients with CAP due to Streptococcus pneumoniae, as well as in patients with CAP of 
different microbial aetiology. The DS CRB-65 can easily be used in hospitals EDs, or 
outside the acute hospital, as no laboratory tests are needed. 
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7 ASPECTS FOR THE FUTURE 
The fatality rate is still high in bacteraemic pneumococcal disease, despite access to 
efficient antibiotics, intensive care, as well as mechanical ventilation for the critically 
ill. Our knowledge regarding underlying chronic diseases and their impact on patients 
who present with acute pneumococcal disease, is increasing. However, socioeconomic 
factors such as income, occupation, education, mental status, social network, gender e t 
c, are all factors difficult to measure in relation to infectious diseases. Research 
regarding these matters in relation to pneumococcal disease is an issue of great 
importance. 
In many severe infections that require antibiotic treatment for weeks, or even many 
months, e.g. osteomyelitis, tuberculosis, endocarditis, or infections associated with 
foreign material, have combinations of antibiotics proven more successful than single 
antibiotic treatment. In CAP due to pneumococci different antibiotic combinations have 
been tested, however not yet been proven beneficial in decreasing the CFR. Hopefully, 
future studies can cast some light regarding if, or which antibiotic combinations, that 
may benefit patients who suffer from serious pneumococcal disease. 
Scoring systems to grade seriousness of acute medical conditions are often used in 
hospitals EDs to facilitate safe and effective treatment, as well as to decide level of 
care. The new scoring system proposed to be used in patients with CAP, DS CRB-65, 
needs to be tested in future, preferably prospective studies with sufficient statistical 
power. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  48
8 SWEDISH SUMMARY 
Bland infektionssjukdomar är samhällsförvärvad lunginflammation den vanligast 
förekommande infektionssjukdomen som leder till vård på sjukhus. Det är en sjukdom 
som i första hand drabbar de yngsta, de äldsta, de fattigaste och de sjukaste i samhället. 
Insjuknande i samhällsförvärvad lunginflammation hos befolkningen (incidens) 
uppskattas hos vuxna i västvärlden uppgå till 5-12 personer per 1000 personer och år 
(0,5-1,2 %). Mellan 20 % och 40 % av de personer som drabbats av samhällsförvärvad 
lunginflammation behöver läggas in på sjukhus för vård. Dödligheten är under 1 % för 
personer som kan vårdas i hemmet. Hos sjukhusvårdade patienter med 
samhällsförvärvad lunginflammation kan dödligheten stiga till 50 % hos de allra 
sjukaste. I Europa beräknas den årliga kostnaden för samhällsförvärvad 
lunginflammation uppgå till över 10 miljarder Euro.  
Den vanligaste mikrobiella orsaken till samhällsförvärvad lunginflammation är 
pneumokockbakterien (Streptococcus pneumoniae), som även ger upphov majoriteten 
av alla dödsfall i samhällsförvärvad lunginflammation. Innan antibiotika fanns 
tillgängligt för att behandla infektionssjukdomar kunde dödligheten i 
samhällsförvärvad lunginflammation, där patienter led av blodförgiftning med 
pneumokocker, ibland överstiga 80 %. Vid lunginflammation där pneumokocker har 
hittats i blodet på patienten kan man idag med hjälp av verksamma antibiotika och 
tillgång till intensivvård sänka dödligheten till mellan 5 % och 25 %. 
 
I denna avhandling finns fyra delarbeten i form av forskningsstudier presenterade. 
 
I den första forskningsstudien deltog 460 patienter från fem länder i en prospektiv 
multicenterstudie. Alla patienter hade pneumokockbakterier i blod och 12 % av alla 
patienter dog under tiden de var inlagda på sjukhus. De vanligast förekommande 
diagnoserna var samhällsförvärvad lunginflammation, bakteremi (bakterier i blod) utan 
funnet focus och hjärnhinneinflammation. Då patienterna lades in på sjukhus noterades 
flera oberoende prognostiska riskfaktorer som var kopplade till risken att dö under 
vårdtiden. Dessa riskfaktorer för död var – ålder över 65 år, kronisk lungsjukdom, 
vårdhemsboende, minst två lunglober infekterade (visar hur utbredd 
lunginflammationen är med hjälp av röntgen) samt behov av respiratorhjälp för att 
syresätta blodet.  
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I den andra forskningsstudien deltog 340 patienter som hade samhällsförvärvad 
lunginflammation och samtidigt pneumokocker i blodet. Målet med studien var att 
undersöka om man med kombination av två olika antibiotikasorter (β-laktamantibiotika 
som t ex penicillin eller cefalosporin i combination med med makrolidantibiotika, till 
exempel erytromycin, klaritromycin), kunde minska dödligheten i svår 
lunginflammation med pneumokocker som växer i blodet. Trots omfattande statistisk 
analys kunde vi inte påvisa att kombination av antibiotika, enligt ovan, minskade 
dödligheten jämfört med om man behandlade med β-laktamantibiotika, som t ex 
penicillin, vilket är förstahandsbehandling vid infektion med pneumokocker.  
I den tredje och i den fjärde delstudien deltog patienter med samhällsförvärvad 
lunginflammation. Målet med studie tre och fyra var att på ett enkelt, men säkert sätt, 
bedöma patienters behov av vård på sjukhus med hjälp av ett poängbaserat 
bedömningssystem. Forskningsstudie tre inkluderades 375 patienter där alla patienter 
hade samhällsförvärvad lunginflammation och pneumokockbakterier i blodet. I 
delstudie fyra deltog 1172 patienter (830 patienter blev inlagda på sjukhus och 342 
patienter kunde vårdas i hemmet). Patienterna i delstudie fyra hade samhällsförvärvad 
lunginflammation orsakad av olika sorters bakterier och virus.  
Det behövs inga blodprover eller rtg-undersökningar för att kunna använda 
bedömningssystemet, som vi valt att kalla DS CRB-65. Varje bokstav och siffrorna 65 
anger en parameter. Nödvändiga uppgifter om eventuella underliggande sjukdomar (D) 
erhålls via patienten, anhöriga, eller journalsystem. Mängden syre i blodet (S) 
kontrolleras med”en klämma på fingret”och med hjälp av några enkla frågor bedömer 
om patienten är förvirrad (C). Man kontrollerar även andningsfrekvens (R), blodtryck 
(B) och ålder (65) där ålder 65 år, eller äldre ger 1 poäng. Varje mätt parameter som 
uppfylls ger 1 poäng (0-6 poäng). Om patienten har låga poäng och inget talar däremot 
kan patienten vårdas i hemmet, vid höga poäng (minst 3) vårdas patienten bäst på 
sjukhus. 
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